Segment Information - Summary of Company's Financial Data for Development and Commercialization of Pharmaceutical Products Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting Information [Line Items]
Net product sales	$ 4,283,979	$ 2,654,186	$ 11,116,279	$ 6,941,042
Cost of goods sold	101,977	104,024	311,269	238,031
Eversana profit sharing	5,314,370	3,824,142	14,746,777	10,697,128
Interest income	107,507	99,294	338,894	226,353
Interest expense (non-cash)	126,027	126,027	373,973	375,342
Pharmaceutical Products [Member]
Segment Reporting Information [Line Items]
Net product sales	4,283,979	2,654,186	11,116,279	6,941,042
Cost of goods sold	(101,977)	(104,024)	(311,269)	(238,031)
Eversana profit sharing	(3,640,048)	(2,277,308)	(9,447,180)	(5,921,230)
Employee expenses	(619,572)	(561,258)	(1,889,466)	(1,819,230)
Professional fees	(687,161)	(546,740)	(2,319,005)	(1,674,494)
Stock-based compensation	(105,056)	(131,587)	(293,693)	(512,194)
Sales and marketing expenses	(179,003)	(194,201)	(540,556)	(561,293)
Other operating expenses	(88,850)	(124,725)	(313,393)	(225,009)
Interest income	107,507	99,294	338,894	226,353
Interest expense (non-cash)	(126,027)	(126,027)	(373,973)	(375,342)
Total segment costs loss and net loss	$ (1,156,208)	$ (1,312,390)	$ (4,033,362)	$ (4,159,428)